MICs to tigecycline and 12 antimicrobials were performed by microdilution method, against
2423 nonduplicate pathogens recently isolated in 17 Greek hospitals. The Food and Drug …

The Tigecycline Evaluation and Surveillance Trial (TEST Program) determined the in vitro
activity of tigecycline over a large population of organisms from geographically diverse sites …

Tigecycline and comparators were tested by the reference broth microdilution method
against 33 348 non-duplicate bacterial isolates collected prospectively in 2016 from medical …

Tigecycline, a new glycylcycline antibiotic, has shown promising in vitro activity against
many common pathogens, including multidrug-resistant strains. To determine the activity of …

Tigecycline was initially approved by the US Food and Drug Administration (FDA) in June
2005. We assessed the evolution of tigecycline in vitro activities since the initial approval of …

The Tigecycline Evaluation and Surveillance Trial began in 2004 to monitor the in vitro
activity of tigecycline and comparator agents against a global collection of Gram-negative …

Tigecycline is the first glycylcycline antimicrobial in phase III clinical trials. This study
compares the in vitro activity of tigecycline to 12 other predominately broad-spectrum …

The current surveillance establishes the activity profile of tigecycline against recent clinical
US isolates of target pathogens. Findings from a distributed surveillance that utilized Etest …

Tigecycline activity was evaluated against 11808 pathogens isolated from 30 US medical
centers. Susceptibility testing was performed by reference broth microdilution methods …

Abstract Background: The Tigecycline Evaluation and Surveillance Trial (TEST) global
surveillance program has been designed to assess the in vitro activity of the broad-spectrum …